LISA PHARMA
ActiveSummary
The computed 12-month bankruptcy probability of LISA PHARMA is 1.6% (moderate). The 2025 annual accounts show equity of €153,372 and a net result of €25,740. Equity is growing by about 65% per year across the filed financial years. Its solvency ranks better than 31% of 9,633 sector peers (NACE 82, financial year 2025). The company has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals.
Group and network
Connections & network
1 current directorThe network starts from this company’s directors. Other companies they run appear here as nodes.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.